WO2009069291A1 - Composition prophylactique et/ou thérapeutique pour une maladie causée par l'inhalation de la fumée du tabac - Google Patents

Composition prophylactique et/ou thérapeutique pour une maladie causée par l'inhalation de la fumée du tabac Download PDF

Info

Publication number
WO2009069291A1
WO2009069291A1 PCT/JP2008/003480 JP2008003480W WO2009069291A1 WO 2009069291 A1 WO2009069291 A1 WO 2009069291A1 JP 2008003480 W JP2008003480 W JP 2008003480W WO 2009069291 A1 WO2009069291 A1 WO 2009069291A1
Authority
WO
WIPO (PCT)
Prior art keywords
prophylactic
inhalation
therapeutic composition
tobacco smoke
disease caused
Prior art date
Application number
PCT/JP2008/003480
Other languages
English (en)
Japanese (ja)
Inventor
Satoru Furukawa
Original Assignee
Satoru Furukawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Satoru Furukawa filed Critical Satoru Furukawa
Publication of WO2009069291A1 publication Critical patent/WO2009069291A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne une composition prophylactique et/ou thérapeutique pour la maladie pulmonaire obstructive chronique (COPD), qui est une maladie causée par l'inhalation de la fumée du tabac. Une composition est préparée, qui comprend, en tant qu'ingrédient actif, au moins une substance sélectionnée dans le groupe constitué de l'acide orotique, l'acide orotidylique (un dérivé de l'acide orotique), l'orotidine et le monophosphate d'uridine (UMP), et leurs sels inorganiques et leurs sels organiques. Dans la préparation, il est préférable que la composition comprenne également un agent antioxydant, tel que la glutathione, la N-acétylcystéine, la coenzyme Q10, l'acide α-lipoïque, la vitamine C, la vitamine E, le polyphénol et le caroténoïde. La composition prophylactique et/ou thérapeutique peut être administrée par voie orale ou par inhalation.
PCT/JP2008/003480 2007-11-26 2008-11-26 Composition prophylactique et/ou thérapeutique pour une maladie causée par l'inhalation de la fumée du tabac WO2009069291A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007305017A JP2011026204A (ja) 2007-11-26 2007-11-26 タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物
JP2007-305017 2007-11-26

Publications (1)

Publication Number Publication Date
WO2009069291A1 true WO2009069291A1 (fr) 2009-06-04

Family

ID=40678202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/003480 WO2009069291A1 (fr) 2007-11-26 2008-11-26 Composition prophylactique et/ou thérapeutique pour une maladie causée par l'inhalation de la fumée du tabac

Country Status (2)

Country Link
JP (1) JP2011026204A (fr)
WO (1) WO2009069291A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012081604A1 (fr) * 2010-12-15 2012-06-21 キリンホールディングス株式会社 Composition contenant de l'acide orotique et son procédé de production
WO2016065419A1 (fr) * 2014-10-28 2016-05-06 Medlab Ip Pty Ltd Traitement de la dépression et des troubles dépressifs
WO2018207929A1 (fr) * 2017-05-12 2018-11-15 株式会社古川リサーチオフィス Améliorant du degré de saturation artérielle en oxygène
CN115814090A (zh) * 2022-11-22 2023-03-21 广州医科大学附属第一医院 烟草引发炎症的药物新靶点
US11890315B2 (en) 2017-11-17 2024-02-06 Renovion, Inc. Stable ascorbic acid compositions and methods of using same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2640485T3 (es) * 2011-08-12 2017-11-03 Universitätsklinikum Freiburg Uridina y análogos de uridina para el uso en el tratamiento de la enfermedad pulmonar obstructiva crónica
GB2524831A (en) * 2014-04-04 2015-10-07 Ermes Medical Company Ltd New pharmaceutical use
JP6811983B2 (ja) * 2016-08-18 2021-01-13 株式会社古川リサーチオフィス 網膜神経節細胞死抑制活性を有する経口用組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505553A (ja) * 1996-11-07 2001-04-24 インスパイアー ファーマシューティカルズ，インコーポレイティド ウリジン三リン酸および関連化合物で気管支炎を治療する方法
WO2002100409A1 (fr) * 2001-06-11 2002-12-19 Kyowa Hakko Kogyo Co., Ltd. Compositions anti-inflammatoires et antitussives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505553A (ja) * 1996-11-07 2001-04-24 インスパイアー ファーマシューティカルズ，インコーポレイティド ウリジン三リン酸および関連化合物で気管支炎を治療する方法
WO2002100409A1 (fr) * 2001-06-11 2002-12-19 Kyowa Hakko Kogyo Co., Ltd. Compositions anti-inflammatoires et antitussives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Encyclopedic Reference of Molecular Pharmacology", 2004, SPRINGER-VERLAG, pages: 784 - 790 *
ANDERSON C.M. ET AL.: "Potential signalling roles for UTP and UDP: sources, regulation and release of uracil nucleotides", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 18, 1997, pages 387 - 392 *
LAZAROWSKI E.R. ET AL.: "Direct Demonstration of Mechanically Induced Release of Cellular UTP and Its Implication for Uridine Nucleotide Receptor Activation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 39, 1997, pages 24348 - 24354 *
PELS RIJCKEN W.R. ET AL.: "Pyrimidine metabolism and sugar nucleotide synthesis in rat liver", BIOCHEMICAL JOURNAL, vol. 266, 1990, pages 777 - 783 *
SAIAG B. ET AL.: "Lack of uptake, release and action of UTP at sympathetic perivascular nerve terminals in rabbit ear artery", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 358, 1998, pages 139 - 145 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012081604A1 (fr) * 2010-12-15 2012-06-21 キリンホールディングス株式会社 Composition contenant de l'acide orotique et son procédé de production
WO2016065419A1 (fr) * 2014-10-28 2016-05-06 Medlab Ip Pty Ltd Traitement de la dépression et des troubles dépressifs
AU2015337800B2 (en) * 2014-10-28 2021-05-27 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
US11135181B2 (en) 2014-10-28 2021-10-05 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
WO2018207929A1 (fr) * 2017-05-12 2018-11-15 株式会社古川リサーチオフィス Améliorant du degré de saturation artérielle en oxygène
JPWO2018207929A1 (ja) * 2017-05-12 2020-01-23 株式会社古川リサーチオフィス 動脈血中酸素飽和度の向上剤
US11331318B2 (en) 2017-05-12 2022-05-17 Furukawa Research Office Co., Ltd. Arterial oxygen saturation degree improver
US11890315B2 (en) 2017-11-17 2024-02-06 Renovion, Inc. Stable ascorbic acid compositions and methods of using same
CN115814090A (zh) * 2022-11-22 2023-03-21 广州医科大学附属第一医院 烟草引发炎症的药物新靶点
CN115814090B (zh) * 2022-11-22 2024-05-24 广州医科大学附属第一医院 烟草引发炎症的药物靶点

Also Published As

Publication number Publication date
JP2011026204A (ja) 2011-02-10

Similar Documents

Publication Publication Date Title
WO2009069291A1 (fr) Composition prophylactique et/ou thérapeutique pour une maladie causée par l'inhalation de la fumée du tabac
WO2012015810A3 (fr) Compositions pharmaceutiques contenant du pemetrexed présentant une stabilité en stockage prolongé
WO2008002245A8 (fr) Nouveaux composés 385
WO2008035359A3 (fr) Acide oxyminophénoxyalcanoïque et dérivés de l'acide phenylalcanoïque
WO2007107470A3 (fr) Pyrazoles utiles comme inhibiteurs de 11-beta-hsd-1
WO2006119498A3 (fr) Compositions pharmaceutiques avec liberation synchronisee de l'agent solubilisant
WO2006082523A3 (fr) Compositions pharmaceutiques de metformine
WO2009010416A3 (fr) Inhibiteurs de 11b-hydroxystéroïde déshydrogenase
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2008002244A8 (fr) Nouveaux composés 384
WO2009074950A3 (fr) Nouveaux dérivés du thiophène
NZ592383A (en) Pharmaceutical composition of a potent hcv inhibitor for oral administration
SG156613A1 (en) Use of mitochondrially targeted antioxidant in the treatment of liver diseases and epithelial cancers
WO2007090882A3 (fr) Compositions pharmaceutiques
WO2007020204A3 (fr) Formulations d'hydrofluorocarbone en solution contenant du chlorhydrate de salbutamol ou du citrate de salbutamol
WO2007114945A3 (fr) Compositions et procedes visant a accroitre le statut antioxydant des animals
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
WO2007093365A3 (fr) Nouvelles arylthiénopyrimidinones à substitution aminoalcool, leur procédé de préparation et leur utilisation comme médicaments
WO2007095043A3 (fr) Formulations pharmaceutiques
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
WO2010031832A3 (fr) Combinaisons synergiques d'un inhibiteur macrocyclique de hcv et d'un dérivé d'acide thiophène-2-carboxylique
WO2008133330A1 (fr) Préparation solide stable comprenant un dérivé de 4,5-époxymorphinane
WO2006077024A3 (fr) Derives de 5-aminoindole
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08854676

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08854676

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP